4506 — Sumitomo Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapTurnaround

Annual income statement for Sumitomo Pharma Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	560,035	555,544	314,558	398,832	453,294
Cost of Revenue
Gross Profit	402,919	377,050	188,030	245,502	256,893
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	499,801	632,523	669,417	370,028	345,956
Operating Profit	60,234	-76,979	-354,859	28,804	107,338
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	82,961	-47,920	-323,114	17,611	100,344
Provision for Income Taxes
Net Income After Taxes	40,600	-96,714	-314,929	23,635	106,865
Minority Interest
Net Income Before Extraordinary Items
Net Income	56,413	-74,512	-314,969	23,634	106,865
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	56,413	-74,512	-314,969	23,634	106,865
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	142	-150	-506	41.1	269
Dividends per Share